| 17.39 -0.31 (-1.75%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 23.28 | 1-year : | 27.19 |
| Resists | First : | 19.93 | Second : | 23.28 |
| Pivot price | 16.75  |
|||
| Supports | First : | 16.5 | Second : | 14.39 |
| MAs | MA(5) : | 18.07 |
MA(20) : | 16.45 |
| MA(100) : | 20.12 |
MA(250) : | 27.83 |
|
| MACD | MACD : | 0.1 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 64.2 |
D(3) : | 74.7 |
| RSI | RSI(14): 51.4 |
|||
| 52-week | High : | 61.06 | Low : | 13.69 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TECX ] has closed below upper band by 37.6%. Bollinger Bands are 6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 18.37 - 18.52 | 18.52 - 18.62 |
| Low: | 16.62 - 16.77 | 16.77 - 16.88 |
| Close: | 17.18 - 17.43 | 17.43 - 17.59 |
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
Fri, 17 Oct 2025
Tectonic Therapeutic, Inc. (TECX) Stock Analysis: A Biotech Gem with a 351.84% Potential Upside - DirectorsTalk Interviews
Fri, 03 Oct 2025
Tectonic Therapeutic, Inc. (TECX) Stock Analysis: A Biotech Gem with 422.95% Upside Potential - DirectorsTalk Interviews
Wed, 03 Sep 2025
Oppenheimer initiates Tectonic Therapeutics stock with Outperform rating - Investing.com
Wed, 03 Sep 2025
Tectonic Therapeutic a new outperform at Oppenheimer on heart drug asset - Seeking Alpha
Wed, 03 Sep 2025
Insider Purchases Worth US$62.6m See Losses As Tectonic Therapeutic Market Value Drops To US$478m - simplywall.st
Thu, 28 Aug 2025
GPCR-focused Biotech Tectonic Therapeutic Sets Major Conference Schedule: CEO, CFO to Present - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 19 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 38.3 (%) |
| Held by Institutions | 65 (%) |
| Shares Short | 2,850 (K) |
| Shares Short P.Month | 2,590 (K) |
| EPS | 4.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 15.15 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19 % |
| Return on Equity (ttm) | -29.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.89 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -64 (M) |
| Levered Free Cash Flow | -53 (M) |
| PE Ratio | 4.2 |
| PEG Ratio | 0 |
| Price to Book value | 1.14 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|